Background: The role of the multidrug resistance-1 (MDR1 or ABCB1) gene polymorphisms 1236T>C, 2677T>G, and 3435T>C was studied in relation to susceptibility, demographics, and pathological characteristics, as well as their role in the therapeutic response (TR) to prednisone treatment in children with idiopathic nephrotic syndrome (INS).

Material/Methods: The polymorphisms were analyzed using the polymerase chain reaction-restriction fragment length polymorphism method in 46 children with INS and in 100 healthy controls. Different genetic models (codominant, dominant, recessive, and overdominant) were used for testing of associations between polymorphisms and phenotypes.

Results: Statistical analysis showed a significantly increased chance of TR in children carrying 3435TC genotype (OR=5.13, 95% CI=1.18–22.25; overdominant model). Moreover, INS patients under 6 years of age had significantly decreased frequencies of MDR1 1236CC (7.7% vs. 35%, p=0.029) or 2677GG (3.8% vs. 30.0%, p=0.033) genotypes. We also observed that patients with minimal change in disease and patients under 6 years of age at the onset of INS were initial responders more frequently when compared with children with focal segmental glomerulosclerosis and patients ≥6 years old at the onset (p=0.0001, p=0.027, respectively).

Conclusions: These data suggest that prednisone TR may be influenced by histology, age at the onset of INS, and MDR1 3435T>C polymorphism. The MDR1 1236T>C and 2677T>G polymorphisms were significantly associated with age at onset. Larger multicenter studies and studies across other ethnic groups are needed to elucidate the contradictory implications of MDR1 polymorphisms with INS in children.

MeSH Keywords: Genes, MDR • P-Glycoprotein • Polymerase Chain Reaction

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/891366
Background

Nephrotic syndrome (NS) is the most common glomerular pathologic condition encountered in children. In contrast to NS in adulthood, when NS is often secondary to another disorder such as diabetes mellitus, cancer, and chronic inflammatory diseases [1,2], NS in childhood (>12 months age) is largely primary or idiopathic (INS) [3]. The exact reason for this is still not understood. Generally, INS patients present diverse pathological features (e.g., minimal change disease-MCD, focal segmental glomerulosclerosis-FSGS, and mesangial proliferative glomerulonephritis-MesPGN). Variable response to immunosuppressive therapy is observed when glucocorticoids (GC) are recommended as the first-line therapy due to the immune-inflammatory characteristics of the disease. Therapeutic response (TR) to initial steroid therapy has been reported to be 60–95% of children, depending on the geographic area [4,5]. Despite the high initial response rate, relapses occur in 60–90% of the initial responders and some patients remain steroid-dependent. Clinical experience has demonstrated that patients with a poor response to steroids have an unfavorable prognosis and often develop end-stage renal failure [6]. Therefore, it is essential to identify potential factors that contribute to immunosuppressive therapy failure in order to optimize and individualize the treatment of INS.

Changes in the levels and/or function of P-glycoprotein (P-gp) are one of the possible mechanisms of drug resistance that have been published in the literature [7]. P-gp is the product of the MDR1 (alias ABCB1) gene and is an active transmembrane efflux pump for a variety of toxins and many drugs. GC (including prednisone) are also transported by P-gp and may induce P-gp expression [8]. P-gp is found in many organs and tissues (e.g., luminal cells of the lower digestive system, liver, proximal renal tubules, endothelial cells in the blood–brain barrier, placenta, and hematopoietic cells), and the tissue distribution suggests that P-gp plays an important role in excreting potentially toxic or unnecessary xenobiotics and metabolites from the body and the cells, and has significant pharmacokinetic and pharmacodynamic implications for P-gp substrates [9]. P-gp may also actively participate in the chronic inflammation in autoimmune diseases; it is up-regulated by cytokines, probably participates in releasing certain inflammatory mediators, and is probably involved in the cell activation/death pathways [10,11].

Recent experimental and clinical studies have shown that gene expression and the activity of P-gp may be affected by MDR1 gene polymorphisms. Three single-nucleotide polymorphisms (SNPs) seem to have the most important clinical relevance: 1236T>C (rs1128503, MAF/minor allele frequency: T=0.422, silent SNP); 2677T>G/A (rs2032582, MAF: T=0.340, Ser893Ala/Thr); and 3435T>C (rs1045642, MAF: T=0.397, silent SNP). The silent 3435T>C polymorphism may have some effect on DNA structure, RNA stability, and P-gp function, or it is in linkage disequilibrium with other functional MDR1 polymorphisms [12–14]. In most studies, the T allele is associated with decreased P-gp function. The non-synonymous SNP (2677T>G/A) has also been found to be associated with altered expression, activity and the substrate specificity of P-gp [15,16]. It is speculated that patients who carry the T/A are more resistant to drugs [17]. The silent 1236T>C polymorphism may affect translation regulation, RNA stability, or other molecular mechanisms. It may also have an indirect effect, being linked to a causal variant. In a recent study, it was shown that TT genotype minimizes P-gp activity in a substrate-dependent manner [18].

Only a few studies in different ethnic populations have evaluated the distribution of the MDR1 polymorphisms (1236T>C, 2677T>G/A, and 3435T>C) in children with NS and controls to investigate their usefulness as markers of responsiveness of the disease to steroids, and they have shown inconsistent results [19–22].

On the basis of published data, our study focused on determining the relevance of the MDR1 (1236T>C, 2677T>G, and 3435T>C) polymorphisms and haplotypes to childhood INS susceptibility, selected demographic and clinical characteristics of INS, and TR to prednisone-based therapy in Slovak children.

Material and Methods

Study population and data collection

The study was performed in 2 groups of participants. The patient group comprised 46 children with a diagnosis of INS treated and/or monitored in the Pediatric Nephrology Centre at the Department of Pediatrics and Adolescent Medicine of the Faculty of Medicine of P. J. Safarik University in Kosice, Slovakia. The control group comprised 100 healthy children without any known chronic disease. Blood samples from both groups were collected during routine control biochemical tests or routine preventive pediatric examination at the same department from January 2010 to January 2014.

Participation was voluntary and could be cancelled by any individual at any time during the study (according to the Helsinki II declaration). The local ethics committee approved the research protocol for this study and all volunteers and/or their parents signed the study informed consent form.

Data evaluation was based on analysis of retrospective charts. All INS patients were followed up for at least 2 years. The inclusion criteria for the patient group were a fulfilled definition of INS, and TR to prednisone-based therapy in Slovak children.
INS (massive proteinuria of ≥40 mg/h/m^2 and hypo-albuminemia of ≤2.5 g/dL), absence of secondary cause of nephrotic syndrome, and age 1–18 years. All cases were Slovaks from different regions of Eastern Slovakia.

All patients were treated with the standard initial steroid therapy, consisting of daily dosage of prednisone of 60 mg/m^2/day for 4 weeks followed by 40 mg/m^2/day on alternate days for an additional 4 weeks. Relapses were treated with daily prednisone dose of 60 mg/m^2/day until urine protein test results were negative or trace for 3 consecutive days, followed by 40 mg/m^2/day on alternate days for 4 weeks, and finally by various steps of tapering-off on alternate days.

The following definitions were considered for classification of response pattern to steroid therapy [3,4]:
1. Initial steroid response (RE-responders): attainment of complete remission (CR) within the initial 4 weeks of GC therapy. CR was defined as urinary protein excretion <4 mg/h/m^2; nil or trace by dipstick on spot sample for 3 consecutive days.
2. Initial steroid resistance (NRE-non-responders): failure to achieve complete remission following at least 4 weeks of corticosteroid therapy at a dose 60 mg/m^2/day.
3. Steroid dependence: occurrence of 2 consecutive relapses during steroid therapy or within 14 days of its cessation.
4. Frequent relapse: 2 or more relapses within the first 6 months of initial response, or 4 or more relapses in any 12-month period.

All steroid-resistant patients were successfully screened for NPHS1 and WT1 mutations, with negative results. Renal biopsy was performed in all patients except 1 (because of a hypoplastic kidney).

**DNA extraction and genotyping**

Genomic DNA was extracted from peripheral venous blood by using Wizard® Genomic DNA Purification Kit (Promega Corporation, USA). The SNPs in MDR1 were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay using the following primer sequences and corresponding restriction enzymes; (1) 1236T>C, 5'-TTACCCATCTCGAAAAGTAAAGT-3' – forward, 5'-TGCCCCACCTGCACTCTTACTTC-3' – reverse (HaeII); (2) 2677T>G, 5'-TATACCCAGAATAGCAAATCTTG-3' – forward, 5'-CATATTTAGTGGACTCCCTCTTCA-3' – reverse (Hpy188I); (3) 3435T>C, 5'-TGTCTTCGCTGTATGG-3' – forward, R: 5'-AAGCCATGTATGGTGGCCTC-3' – reverse (BfuCl). Due to the low population frequency of the more recently described A allele of 2677T>G/A polymorphism [23,24], this variant was not genotyped in the present study. The same PCR reaction pattern was used for each SNP. The PCR reaction mixture contained approximately 200 ng of genomic DNA, 1×PCR Buffer with 1.5 mM MgCl2 (Solis BioDyne, Estonia), 200 μM deoxynucleotide triphosphate mix (Jena Bioscience, Germany), 0.4 μM of each primer (Sigma-Aldrich, Germany), and 1.0 U HOT FIREPol® DNA Polymerase (Solis BioDyne, Estonia). PCR-grade water was added, bringing the final volume to 25 μL. The amplification consisted of an initial polymerase activation step for 15 min at 95°C and initial denaturation step for 30 s at 95°C followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 56°C for 30 s, and extension at 72°C for 30 s. Terminal elongation was performed at 72°C for 3 min. The PCR products were digested at 37°C overnight using 10 units of appropriate restriction endonuclease (New England BioLabs, UK). The restriction fragments obtained were separated by electrophoresis on a 3% agarose gel for 90 min at 140 V and analyzed after staining with GelRed (Biotium, USA) under ultraviolet light. The electrophoretic pattern for each SNP was: (1) 1236T>C, 5'-TTACCCATCTCGAAAAGTAAAGT-3' – forward, 5'-TGCCCCACCTGCACTCTTACTTC-3' – reverse (HaeII); (2) 2677T>G, 5'-TATACCCAGAATAGCAAATCTTG-3' – forward, 5'-CATATTTAGTGGACTCCCTCTTCA-3' – reverse (Hpy188I); (3) 3435T>C, 5'-TGTCTTCGCTGTATGG-3' – forward, R: 5'-AAGCCATGTATGGTGGCCTC-3' – reverse (BfuCl).
analyze the association between a polymorphism and phenotype. The most commonly used model, the codominant model, is presented for all SNPs. The best-fitting genetic model was selected on the basis of Akaike’s information criterion. Results from the model chosen were then discussed. Odds ratios (OR) and the corresponding 95% confidence intervals (95% CI) were used for calculating the relative associations.

The SNPStats program was used to examine haplotype frequency estimates [25].

**Results**

**Clinical characteristics of the participants**

Of the 46 patients enrolled in the study, 32 (69.57%) were males and 14 (30.43%) were females (male: female ratio: 2.29:1). The mean age at onset of INS was 6.42±4.72 years. Twenty-six children were <6 years old at the onset of disease. Among the total of 46 children with INS, 33 were initial RE (71.74%) and 13 were initial NRE (28.26%). From initial RE, 27 participants (81.82%) were frequent relapers and/or steroid-dependent INS patients.

MCD was found in 32/46 (69.57%) children, FSGS in 11/46 (23.91%), and MesPGN in 2/46 (4.35%, 1 male and 1 female) of the remaining children.

Clinical and pathological characteristics of RE and NRE are shown in Table 1. We observed significant association between histological pattern and age at onset of INS with the initial steroid response. Patients with MCD were initial RE more frequently when compared with children with FSGS (p<0.0001).

| Variable | RE N=33 (%) | NRE N=13 (%) | OR (95% CI) | p value |
|----------|-------------|--------------|-------------|---------|
| Age: <6 years | 22 (66.7) | 4 (30.8) | 1.00 (Ref.) |         |
| ≥6 years | 11 (33.3) | 9 (69.2) | 4.5 (1.13–17.94) | 0.027* |
| Sex: Males | 24 (72.7) | 8 (61.5) | 1.00 (Ref.) |         |
| Females | 9 (27.3) | 5 (38.5) | 1.67 (0.43–6.46) | 0.493 |
| Histology: MCD | 29 (87.9) | 3 (23.1) | 1.00 (Ref.) | FSGS vs. MCD |
| FSGS | 2 (6.1) | 9 (69.2) | 43.50 (6.25–302.6) | <0.0001* |
| MesPGN | 1 (3.0) | 1 (7.7) |         |         |
| Origin: Town | 14 (42.4) | 9 (69.2) | 1.00 (Ref.) |         |
| Village | 19 (57.6) | 4 (30.8) | 0.33 (0.08–1.28) | 0.102 |

**Table 1. Clinical characteristics of patients with idiopathic nephrotic syndrome.**

RE – responders; NRE – non-responders; OR – odds ratio; CI – confidence interval; MCD – minimal change disease; FSGS – focal segmental glomerulosclerosis; MesPGN – mesangial proliferative glomerulonephritis; Ref. – reference; * a significant association.

Moreover, a significantly higher frequency of RE was observed in patients younger than 6 years of age at onset of INS (p=0.027).

The control group comprised 100 healthy children (54 males and 46 females) with a mean age of 7.89±6.31. There were no significant differences in distributions of age and sex between controls and INS patients.

**Genotype and allelic distribution of MDR1 polymorphisms**

All obtained blood samples were successfully genotyped for MDR1 SNPs (3435T>C, 2677T>G, and 1236T>C). Overall genotype and allele frequencies for the tested MDR1 polymorphisms in patients and control subjects are shown in Table 2. The frequency of MDR1 1236T and 3435T alleles in Slovak control participants was higher when compared with 1236C and 3435C alleles. For the 2677T>G polymorphism, the G allele was more frequent than the T allele in the control group.

There was no significant difference in the distribution of genotypes and alleles in all 3 SNPs between the patient group and the control group. The test for HWE showed no significant deviation from the Hardy-Weinberg equilibrium either in the total patient sample (3435T>C: p=0.9872; 2677T>G: p=0.1958; and 1236T>C: p=0.6675) or the control sample (3435T>C: p=0.9335; 2677T>G: p=0.7651; and 1236T>C: p=0.3428).

**Patient characteristics according to MDR1 polymorphisms**

Distributions of genotypes and alleles of MDR1 gene polymorphisms among INS patients with respect to age at onset are shown in Table 3. INS patients less than 6 years old had decreased frequencies of MDR1 1236CC (7.7% vs. 35%, p=0.029)
and MDR1 2677GG (3.8% vs. 30%, p=0.041) genotypes. The risk of early onset of INS was significantly lower among patients carrying 1236CC than patients carrying 1236TT+TC (OR=0.15; 95% CI=0.03-0.86; recessive model). Similarly, patients carrying 2677GG genotypes had lower risk of developing INS at a younger age than patients carrying TG+TT genotype (OR=0.09; 95% CI=0.01-0.86; recessive model). The difference in allele frequencies between INS participants <6 years old and ≥6 years old was not statistically significant.

There was no significant association between 3435T>C polymorphism and age of onset under any tested genetic models. No other significant differences were found across clinical and pathological characteristics (sex, histopathology, number of relapses, and origin) differentiated according to genotypes and alleles of MDR1 polymorphisms (data not shown).

### Haplotype analysis

Haplotype analysis of the 3 MDR1 polymorphisms (1236T>C, 2677T>G, and 3435T>C) revealed 7 major haplotypes. TTT haplotype was the most frequent haplotype in the patients and control group. There were no significant differences in the distribution of these haplotypes between INS patients and the controls (Table 5). Moreover, we did not observe any significant difference in the distribution of these haplotypes between initial steroid responders and non-responders. No statistically significant associations were found between non-frequent relapers and frequent relapsers and/or steroid-dependent INS patients and MDR1 genotypes or alleles (data not shown).

### Table 2. Distributions of genotypes and alleles of MDR1 gene polymorphisms among control subjects and INS patients.

| Genotype | Controls N=100 (%) | INS patients N=46 (%) | OR (95% CI) | p value |
|----------|--------------------|-----------------------|-------------|---------|
| 1236T>C  |                    |                       |             |         |
| TT       | 31 (31.0)          | 11 (23.9)             | 1.00 (Ref.) |         |
| TC       | 41 (41.0)          | 26 (56.5)             | 1.79 (0.77-4.16) | 0.176 |
| CC       | 28 (28.0)          | 9 (19.6)              | 0.91 (0.33-2.51) | 0.849 |
| T allele | 103 (51.5)         | 48 (52.2)             | 1.00 (Ref.) |         |
| C allele | 97 (48.5)          | 44 (47.8)             | 0.97 (0.59-1.60) | 0.915 |
| 2677T>G  |                    |                       |             |         |
| TT       | 23 (23.0)          | 10 (21.7)             | 1.00 (Ref.) |         |
| TG       | 49 (49.0)          | 29 (63.0)             | 1.36 (0.57-3.26) | 0.488 |
| GG       | 28 (28.0)          | 7 (15.2)              | 0.58 (0.19-1.75) | 0.327 |
| T allele | 95 (47.5)          | 49 (53.3)             | 1.00 (Ref.) |         |
| G allele | 105 (52.5)         | 43 (46.7)             | 0.79 (0.48-1.30) | 0.360 |
| 3435T>C  |                    |                       |             |         |
| TT       | 32 (32.0)          | 15 (32.6)             | 1.00 (Ref.) |         |
| TC       | 52 (52.0)          | 23 (50.0)             | 0.94 (0.43-2.07) | 0.885 |
| CC       | 16 (16.0)          | 8 (17.4)              | 1.07 (0.37-3.04) | 0.904 |
| T allele | 116 (58.0)         | 53 (57.6)             | 1.00 (Ref.) |         |
| C allele | 84 (42.0)          | 39 (42.4)             | 1.02 (0.62-1.68) | 0.950 |

INS – idiopathic nephrotic syndrome; OR – odds ratio; CI – confidence interval; Ref. – reference; a codominant model.
and non-responders (Table 5). Haplotype variations did not influence age at onset of INS or renal pathology (data not shown).

**Discussion**

Genomic medicine, which is the use of information from genomes and their derivatives to guide medical decision making, is a key component of personalized medicine, which is currently a rapidly advancing field of health care [26].

In the present study, we investigated whether 3 known SNPs in the *MDR1* gene (1236T>C, 2677T>G, and 3435T>C) influence INS susceptibility, selected demographics, and pathological characteristics of INS, as well as response to oral prednisone in children from Eastern Slovakia. To our knowledge, this is...
the first study evaluating MDR1 polymorphisms in childhood INS in a Slovak population.

Although the mechanisms of pathogenesis of INS are not clear, the justification for selecting the study of the MDR1 gene in INS was supported by evidence of P-gp distribution and expression in many tissues with barrier function, such as intestinal tissue, liver cells, and proximal tubular epithelial cells (impact on efflux of exogenous and endogenous toxins), as well as in the membranes of leukocytes, which play an important role in the pathogenesis of immune-inflammatory diseases. Wasilewska et al. found significantly higher P-gp expression on CD3-positive lymphocytes in patients with INS than in controls [27]. Moreover, association between MDR1 SNPs and inflammation has been reported [28,29].

| Genotype | NRE N=13 (%) | RE N=33 (%) | OR (95% CI) | p value |
|----------|--------------|-------------|-------------|----------|
| 1236T>C  |              |             |             |          |
| TT       | 5 (38.5)     | 6 (18.2)    | 1.00 (Ref.) |          |
| TC       | 6 (46.2)     | 20 (60.6)   | 2.78 (0.62–12.42) | 0.244   |
| CC       | 2 (15.4)     | 7 (21.2)    | 2.92 (0.41–20.91) | 0.374   |
| T allele | 16 (61.5)    | 32 (48.5)   | 1.00 (Ref.) |          |
| C allele | 10 (38.5)    | 34 (51.5)   | 1.70 (0.67–4.29) | 0.259   |
| 2677T>G  |              |             |             |          |
| TT       | 5 (15.2)     | 5 (38.5)    | 1.00 (Ref.) |          |
| TG       | 23 (69.7)    | 6 (46.2)    | 0.26 (0.06–1.21) | 0.109   |
| GG       | 5 (15.2)     | 2 (15.4)    | 0.40 (0.05–3.13) | 0.622   |
| T allele | 33 (50.0)    | 16 (61.5)   | 1.00 (Ref.) |          |
| G allele | 33 (50.0)    | 10 (38.5)   | 0.63 (0.25–1.58) | 0.318   |
| 3435T>C  |              |             |             |          |
| TT       | 7 (53.9)     | 8 (24.2)    | 1.00 (Ref.) |          |
| TC       | 3 (23.1)     | 20 (60.6)   | 5.83 (1.20–28.38) | 0.030*  |
| CC       | 3 (23.1)     | 5 (15.2)    | 1.46 (0.25–8.43) | 1.000   |
| TT+CC    | 10 (76.9)    | 13 (39.4)   | 1.00 (Ref.) |          |
| TC       | 3 (23.1)     | 20 (60.6)   | 5.13 (1.18–22.25) | 0.022*  |
| T allele | 17 (65.4)    | 36 (54.6)   | 1.00 (Ref.) |          |
| C allele | 9 (34.6)     | 30 (45.5)   | 1.57 (0.61–4.04) | 0.344   |

Table 4. Distributions of genotypes and alleles of MDR1 gene polymorphisms among initial steroid responders and steroid non-responders.

INS – idiopathic nephrotic syndrome; RE – responders; NRE – non-responders; OR – odds ratio; CI – confidence interval; Ref. – reference; a codominant model; b overdominant model; * a significant association.

In the present study, the MDR1 genotype and allele distribution of all 3 tested SNPs were not significantly different between the patient and the control group. There have been only 4 studies conducted to evaluate MDR1 SNPs in children with INS. Similar to our results, other researchers found no association between MDR1 SNPs and INS susceptibility; however, in a Polish study, all INS patients were RE [19,20]. On the other hand, our results are in contrast to studies carried out in different populations, where significant differences in genotype or allele frequencies of MDR1 2677T>G/A and 3435T>C SNPs were observed between INS patients and control subjects. In an Indian population, people with 3435TT genotype and 2677TT+AA genotype appeared to be at increased risk of INS [21]. Similar results were observed in an Egyptian population, where MDR1 2677GT, GA, TT+AA genotypes or T allele,
**Table 5.** Haplotype frequency distribution of MDR1 gene polymorphisms among control subjects and INS patients and with respect to therapeutic response.

| Haplotype | Controls N=100 | INS patients N=46 | p value | RE N=33 | NRE N=13 | p value |
|-----------|----------------|-------------------|---------|---------|----------|---------|
| TTT       | 40.3%          | 47.5%             | 0.240   | 43.5%   | 57.5%    | 0.235   |
| CGC       | 34.1%          | 37.7%             | 0.502   | 40.5%   | 30.6%    | 0.367   |
| CGT       | 12.8%          | 7.9%              | 0.177   | 7.9%    | 7.9%     | 0.951   |
| TTC       | 5.6%           | 3.6%              | 0.433   | 3.4%    | 4.1%     | 0.827   |
| TGT       | 3.3%           | 0.0%              | 0.310   | 0.0%    | 0.0%     | 0.0%    |
| TGC       | 2.3%           | 1.1%              | 0.429   | 1.6%    | 0.0%     | 0.434   |
| CTT       | 1.6%           | 2.2%              | 0.685   | 3.1%    | 0.0%     | 0.709   |

INS – idiopathic nephrotic syndrome; RE – responders; NRE – non-responders.

**MDR1** 3435TT genotype, and T allele genotype frequencies were significantly increased in the INS group [22].

Recently, **MDR1** genotyping has attracted research attention to the possibility of personalized treatment through identification of RE and NRE to a certain class of pharmacotherapy. Selection of tested SNPs in INS patients in this analysis was also based on knowledge of the importance of P-gp in pharmacokinetics or pharmacodynamics of the most commonly used GC in the treatment of the INS, including prednisone [8]. Furthermore, the importance of changes in P-gp expression in relation to TR has been confirmed in INS patients. Significantly lower expression of **MDR1** and P-gp activity in T lymphocytes was detected in steroid- and cyclosporine-sensitive patients compared with resistant patients [30]. In our study, a significantly increased chance of TR to GC was shown in children carrying the **MDR1** 3435CT genotype. No significant differences in the distribution of the **MDR1** 1236T>C and 2677T>G genotypes or alleles between steroid RE and NRE were confirmed. In contrast, Choi et al. found significantly higher frequencies of the **MDR1** 1236CC genotype and C allele in the initial steroid RE than in NRE [20]. A study from India revealed a significant association between steroid TR in INS children and 2677T>G/A polymorphism [21]; a higher frequency of TT+AA genotypes was detectable in NRE in comparison to RE. Similarly, in an Egyptian study, steroid NRE had significantly higher frequencies of **MDR1** 2677GT, GA, and TT+AA genotypes than responsive INS patients [22]. In a Polish study evaluating only steroid RE, a strong association was observed between all tested **MDR1** polymorphisms and time to initial steroid response [19]. The frequencies of 1236TT, 2677TT, and 3435TT genotypes were higher in late RE (time to remission: ≥7 days) than in early RE (time to remission: <7 days). There is currently no clear understanding of exactly how a heterozygous state in 3435T>C SNP confers GC sensitivity. However, some researchers proposed that heterozygous carriers of certain **MDR1** variants are less responsive to infection [31].

The tested **MDR1** polymorphisms are in strong linkage disequilibrium, and haplotype analysis was also evaluated. We identified TTT and CGC haplotypes as the most prevalent. Similar observations have been reported in other populations [19,20]. Our results revealed no significant differences in the distribution of **MDR1** haplotypes between INS patients and controls. Moreover, we did not observe any significant difference in the distribution of these haplotypes between initial steroid RE and NRE. Haplotype variations did not influence age at onset of INS or renal pathology. Similarly, Jafar et al. did not find a significant correlation between **MDR1** haplotypes and TR [21]. However, the haplotype CGC was significantly more common in patients with age at the onset ≥6 years than among patients with an age at the onset <6 years. In contrast, the frequency of the **MDR1** TGC haplotype was significantly higher in the initial steroid NRE than in RE in 2 studies [20,22]. In a Polish study, the TTT haplotype was found to be significantly associated with late oral steroid response [19].

We also tested the influence of **MDR1** SNPs on age at the onset of INS. Interestingly, **MDR1** 1236T>C and **MDR1** 2677T>G SNPs were significantly associated with age at onset. Our preliminary data indicate that genotypes 1236CC or 2677GG could delay early onset of INS but they did not influence the susceptibility to INS. We suppose that these polymorphisms might play a role in pathogenesis of NS in association with some other currently unknown predisposing factor(s). Similarly, Youssef et al. revealed significantly higher frequencies of 2677GG genotype and 3435CC genotype in patients ≥6 years old at the onset of INS [22]. This is in contrast with previous observations showing that age at onset of INS was not influenced by any **MDR1** genotype or allele variations in Polish and Korean children.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License

Indexed in: [Current Contents/Clinical Medicine] [SCJ Expanded] [ISI Alerting System] [ISJ Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]

© Med Sci Monit, 2015; 21: 59-68
[19,20]. In another study, age at onset of INS was correlated only with MDR1 3435T>C SNP [21].

There are a few issues that should be discussed regarding the inconsistent results of studies evaluating P-gp and MDR1 polymorphisms in INS patients. First, studies were done in patients with different ethnicities. It should be noted that P-gp expression and influence of MDR1 SNPs may vary depending on ethnicity and environmental factors [32]. Second, the homogeneity of the tested group is uncertain because of the unknown pathophysiology of the diseases and because of several histological patterns included in the diagnosis of INS. Also, other factors might have influenced the results, such as drug and food interactions [33]. Finally, P-gp has functions other than those directly related to transport activity, and the impact of genetic polymorphisms on these activities may be more pronounced.

Steroid-resistant patients were screened for NPHS1 and WT1 mutations, with negative results, but there are also other gene mutations associated with steroid resistance [34].

In this study, histological pattern and age at onset of INS were significantly associated with the initial steroid response. Patients with MCD were more frequent when compared with children with FSGS, which is in accordance with the data that has been published earlier [31–33]. Furthermore, a significantly higher frequency of RE was observed in patients younger than 6 years of age at the onset of INS. The higher frequency of MCD in patients younger than 6 years of age could be responsible for better TR.

The main limitation of our study was the relatively small sample size, which was because it was a single-center study and there generally are low numbers of children with INS in small populations. Therefore, we cannot exclude the possibility of bias and our preliminary results must be interpreted with caution. Moreover, because of the retrospective patient data collection from medical records and missing information, the evaluation of other parameters describing the clinical course and TR (such as early or late initial response to steroids) could not be made.

Conclusions

Our findings suggest that prednisone therapeutic response may be influenced by histology, age at onset of INS, and by MDR1 3435T>C polymorphism. The MDR1 1236T>C and 2677T>G polymorphisms were significantly associated with age at onset. Larger multicenter studies and studies across other ethnic groups are needed to elucidate the contradictory implications of MDR1 polymorphisms in children with INS.

Acknowledgements

We thank Marta Vysocka and Kamila Samudovska for their skilful technical assistance.

Conflict of interest

The authors declare no conflict of interest in relation to the article.

References:

1. Persazella M: A 58-year-old man with diabetes mellitus and nephrotic syndrome. Hosp Physician, 2002; 18: 39–42
2. Orlowska-Kowalik G, Malecka-Massalska T, Kisiezek A: Elevated serum CA-125 levels in a patient with nephrotic syndrome. Am J Case Rep, 2008; 9: 351–54
3. Bagga A, Mantan M: Nephrotic syndrome in children. Indian J Med Res, 2003; 122: 13–28
4. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM: Time trends of idiopathic nephrotic syndrome. Nephrol Dial Transplant, 1999; 14: 1040–44
5. Seering W, Kist-van Holthe JE, van Rijswijk NH et al: Extending prednisone-sparing therapy in childhood nephrotic syndrome. Pediatr Nephrol, 2001; 16: 1040–44
6. Muntzavni F, Khiavi YS: Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran. Ther Clin Risk Manag, 2011; 7: 67–71
7. Chen Y, Zhao Y, Wang C et al: Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Med Sci Monit, 2012; 18(10): BR383–88
8. Diler K, Schwab M, Fromm MF: Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis, 2004; 10: 578–83
9. Padowski JM, Pollack GM: Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Methods Mol Biol, 2010; 596: 359–84
10. Richard-Patin Y, Soto-Yega E, Jäkel-Ocampo J, Llorente L: P-glycoprotein in autoimmune diseases. Autoimmun Rev, 2004; 3: 188–92
19. Wasilewska A, Zalewski G, Chyczewski L, Zoch-Zwierz W: MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol, 2007; 22: 44–51

20. Choi HJ, Cho HY, Ro H et al: Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol, 2011; 26: 1981–88

21. Jafar T, Prasad N, Agarwal V et al: MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant, 2011; 26(12): 1968–74

22. Youssef DM, Attia TA, El-Shal AS, Abduelometty FA: Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: Impact on susceptibility and response to steroids. Gene, 2013; 530: 201–7

23. Pechandová K, Buzková H, Slanar O, Perlík F: Polymorphisms of the MDR1 gene in the Czech population. Folia Biol, 2006; 52: 184–89

24. Sole X, Guino E, Valls J et al: SNPStats: a web tool for the analysis of association studies. Bioinformatics, 2006; 22: 1928–29

25. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM: Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, p-glycoprotein). Oncologist, 2007; 12: 927–41

Cascorbi I, Gerloff T, Johne A et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR2 gene in white subjects. Clin Pharmacol Ther, 2001; 69: 169–74

Peichandová K, Buzková H, Slanar O, Perlík F: Polymorphisms of the MDR1 gene in the Czech population. Folia Biol, 2006; 52: 184–89

25. Sole X, Guino E, Valls J et al: SNPStats: a web tool for the analysis of association studies. Bioinformatics, 2006; 22: 1928–29

26. Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl Res, 2009; 154: 277–87

27. Markova S, Nakamura T, Sakaeda T et al: Genotype-dependent down-regulation of gene expression and function of MDR2 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab Pharmacokinet, 2006; 21: 194–200

28. Joshi S, Andersen R, Jespersen B, Rittig S: Genetics of steroid-resistant nephrotic syndrome: a review of mutation spectrum and suggested approach for genetic testing. Acta Paediatr, 2013; 102: 844–56

29. Mubarak M, Kazi JI, Shakeel S et al: The spectrum of histopathological lesions in children presenting with steroid-resistant nephrotic syndrome at a single center in Pakistan. ScientificWorldJournal, 2012; 2012: 618802

30. Sakaeda T: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metabol Pharmacokinet, 2005; 20: 391–414

31. Cizmarikova M. et al.: MDR1 in idiopathic nephrotic syndrome © Med Sci Monit, 2015; 21: 59-68

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]